Entresto® (sacubitril/valsartan)

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.⁶ It is the first-in-class ARNI recommended for the treatment of chronic HFrEF and targets two essential pathways in a complementary manner.^{1, 6}

To learn more, review the Summary of Product Characteristics.⁵

For patients living with chronic heart failure, time is essential, so start with ENTRESTO (sacubitril/valsartan)^1-4

ARNI may be used as part of cornerstone HFrEF therapy with a BB, MRA and SGTL2i in the 2021 ESC guidelines for the treatment of chronic HFrEF patients¹

Icon of a person with a medicine bottle, with text underneath 'and for previously diagnosed patients who are ACEi/ARB-naive'

For patients living with heart failure in place of an ACEi or an ARB...

LEARN MORE

Icon of a person with a stethoscope, with text underneath 'for newly diagnosed chronic HFrEF patients'.

...and for In-Hospital
Patients

LEARN MORE

Image of a heart with 'ENTRESTO demonstrates a comparable safety profile to ACEi (enalapril) 6,9,12', text next to it - safety profile to ACEi (enalapril)

ENTRESTO demonstrates a comparable safety profile to ACEi (enalapril)^6,9,12

Image of a heart with 'Even when patients do not exhibit apparent symptoms, cardiac damage is constantly occurring' - Burden of heart failure , text next to it.

Even when patients do not exhibit apparent symptoms, cardiac damage is constantly occurring⁵

BURDEN OF
HEART FAILURE

Image of a heart with 'ENTRESTO has a dual MoA that simultaneously inhibits vasoconstriction and promotes vasodilation', text next to it - mode of action.

ENTRESTO has a dual MoA that simultaneously inhibits vasoconstriction and promotes vasodilation⁶

MODE OF
ACTION

Image of a hospital with 'Change the disease trajectory in chronic HFrEF' text next to it - disease trajectory.

Change the disease trajectory in chronic HFrEF‌^{1-3, 6-15}

DISEASE
TRAJECTORY

Image of a graph with 'Improve the chronic HFrEF patient’s experience vs ACEi (enalapril)' text next to it - Improvements in quality of life.

Improve the chronic HFrEF patient’s experience vs ACEi (enalapril)^8,11

IMPROVEMENTS IN
QUALITY OF LIFE

Image of a shield with 'National guidelines support ENTRESTO as a 1st line treatment option in chronic HFrEF' text next to it - guidelines.

Guidelines support ENTRESTO as a 1^st line treatment option in chronic HFrEF ^1-3**

GUIDELINES

ENTRESTO is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

** Local reimbursement criteria apply

^†ESC: ARNI may be used first line as part of cornerstone HFrEF therapy with a BB, MRA and SGLT2i for the treatment of chronic HFrEF patients.¹

^‡ACC: ARNIs, ACE-inhibitors or ARBs are recommended as first-line therapy in patients with HFrEF to reduce morbidity and mortality. If patients have chronic symptomatic HFrEF with NYHA class II or III symptoms and they tolerate an ACEi or ARB, they should be switched to an ARNi because of improvement in morbidity and mortality.²

^§DISCLAIMER: This is a US guideline and should not be used to guide treatment decisions in Ireland.

*CaReMe UK: sacubitril/valsartan is recommended as a first-line treatment option for chronic HFrEF where ejection fraction is <35%.

ACC, American College of Cardiology; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BB, beta-blocker; CaReMe UK, Cardio-Renal-Metabolic Partnership UK; ESC, European Society of Cardiology; HFrEF, heart failure with reduced ejection fraction; MoA, mode of action; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SGLT2i, sodium-glucose co-transporter 2 inhibitor.

References:

European Heart Journal (2021) 42, 35993726 ESC GUIDELINES doi:10.1093/1. eurheartj/ehab368
Maddox TM, et al. J Am Coll Cardiol 2021;77(6):772–810.
CaReMe UK HF algorithm. Available at: https://www.britishcardiovascularsociety.org
Ponikowski P, et al. ESC Heart Fail 2014;1(1):4–25.
Mann DL, Bristow MR. Circulation 2005;111(21):2837–2849.
ENTRESTO Summary of Product Characteristics. www.medicines.ie
Claggett B, et al. N Engl J Med 2015;373(23):2289–2290.
Lewis EF, et al. Circ Heart Fail 2017;10(8):e003430.
McMurray JJ, et al. N Engl J Med 2014;371:993–1004.
Solomon SD, et al. JACC Heart Fail 2016;4(10):816–822.
Chandra A, et al. JAMA Cardiol 2018;3(6):498–505.
Velazquez EJ, et al. N Engl J Med 2019;380(6):539–548.
Desai AS, et al. JAMA 2019;322(11):1077–1084.
Wachter R, et al. Eur J Heart Fail 2019;21(8):998–1007.
Januzzi JL Jr, et al. JAMA 2019;322(11):1085–1095.

Rate this content:

November 2024 | IE225992-1

Cardiology

Entresto

Medicines